|
|
|
|
| LEADER |
01618nam a2200229 u 4500 |
| 001 |
EB002000629 |
| 003 |
EBX01000000000000001163530 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Ho, Chuong
|
| 245 |
0 |
0 |
|a Point-of-care cardiac troponin testing in patients with symptoms suggestive of acute coronary syndrome - project protocol
|h Elektronische Ressource
|c Chuong Ho, Karen Cimon, Mohammed Jabr, Monika Mierzwinski-Urban, Fiona Clement, Lesley Soril, Lesley Dunfield, Laura Weeks, Pat Reynard
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c June 2015, 2015
|
| 300 |
|
|
|a 1 PDF file (20 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH optimal use report
|
| 500 |
|
|
|a "PROSPERO Registration Number: CRD42015023442."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK362805
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The aim of this health technology assessment (HTA) is to inform decision-making about the appropriate use of point-of-care (POC) cardiac troponin (cTn) testing. Policy questions such as appropriate settings (rural or remote, ambulance, hospital, emergency room), the timing of testing, and population suitable for POC cTn testing have been raised in Canadian jurisdictions. This HTA will address these questions by evaluating the diagnostic accuracy, clinical utility, and cost-effectiveness of POC cTn testing in patients presenting with acute coronary syndrome (ACS)
|